Commercial Spaceflight Operations - Virgin Galactic has reservations for approximately 675 future astronauts, representing about $188 million in expected future spaceflight revenue upon completion of the spaceflights[27]. - The company completed its sixth commercial spaceflight in six months with 'Galactic 06' in January 2024, marking an unprecedented launch rate[25]. - The company commenced commercial operations with its spaceship, VSS Unity, and launch vehicle carrier aircraft, VMS Eve, in 2023, aiming for 125 space missions per year with its first two spaceships[43]. - The company has flown dozens of research-related missions, with three commercial spaceflights dedicated to research, including 'Galactic 01', 'Galactic 05', and 'Galactic 07'[86]. - The company has generated limited revenue from commercial spaceflight operations, which commenced in June 2023[123]. Next-Generation Spaceships - The next-generation spaceships are expected to enter commercial service in Q4 2026, designed for easier maintenance and increased lifecycles, with a capacity of six passengers, 50% more than the current model[28]. - The next-generation spaceships are designed to feature six passenger seats and are expected to fly twice per week in steady-state operations, with test flights beginning in Q3 2026 and commercial service expected to start in Q4 2026[43]. - The company expects to ramp up to a targeted rate of 125 space missions per year with the first two next-generation spaceships, designed to fly twice a week, starting in Q4 2026[60]. - The company is assembling next-generation spaceships in a new 150,000 square foot facility in Arizona, with additional facilities for rocket motor testing in Mojave, California[93]. Research and Development - The company is exploring opportunities to use a derivative model of its launch vehicle as a High-Altitude, Long-Endurance aircraft for government and research purposes[29]. - Virgin Galactic's commitment to advancing research includes a continuation of its partnership with Purdue University for a research mission scheduled for 2027[32]. - The company is under contract with NASA for research payload flights as part of the NASA Flight Opportunities Program, which began in September 2024 and has an initial term of 5 years[86]. - The company is focused on developing partnerships with luxury travel agencies to enhance sales and reach target audiences effectively[84]. - Investments in new technologies and services are ongoing, with a focus on developing a next-generation launch vehicle, but the expected benefits may not materialize[156]. Financial Performance and Projections - The company incurred net losses of $278.9 million and $346.7 million for the years ended December 31, 2025 and 2024, respectively[123]. - The company expects its operating expenses to increase as it scales spaceflight operations and develops next-generation spaceflight vehicles[124]. - The base price for spaceflight tickets has increased from $450,000 in 2021 to $600,000 in 2023, with recent sales reopening at a price of $750,000 per seat[83]. - The company has a significant backlog of customer demand, having flown 23 paying astronauts and dozens of payloads for research missions as of December 31, 2025[44]. - The company may require substantial additional funding to finance operations, raising doubts about its ability to continue as a going concern[147]. Operational Challenges - The company announced a workforce reduction of approximately 185 employees, constituting about 18% of its workforce, to decrease costs and realign resources[142]. - The company faces potential operational difficulties due to the need to hire and train more employees, which could strain resources and impact financial results[143]. - The company is vulnerable to changes in consumer preferences and economic conditions, which could lead to decreased demand for spaceflight experiences during recessionary periods[144]. - The company relies on a limited number of suppliers for critical raw materials, which could lead to production delays or increased costs if supply is disrupted[149]. - The company faces operational risks from natural disasters and other hazards that could disrupt manufacturing and spaceflight schedules[205]. Regulatory and Compliance Issues - The company is subject to extensive and evolving government laws and regulations, which could materially affect its operations and financial condition[184]. - The company anticipates submitting a license application to the FAA by Q2 2026 to comply with new regulations for commercial spaceflight operations[187]. - The company must maintain compliance with various privacy laws, including the California Consumer Privacy Act (CCPA), which imposes significant obligations[193]. - The company is subject to GDPR compliance, with potential penalties of up to €20 million or 4% of worldwide annual turnover for non-compliance[194]. - The company is subject to risks associated with government contracts, including potential early termination and compliance audits[172]. Competition and Market Dynamics - The company competes with Blue Origin in the commercial spaceflight industry, which is currently evolving and competitive, with increased passenger capacity and flight frequency expected from next-generation spaceships[99]. - The commercial spaceflight industry is expected to be competitive, with potential competition from well-funded entities that may shift focus to suborbital spaceflight[153]. - The company's success in the commercial spaceflight market depends on factors such as pricing, consumer confidence, and the frequency of offerings[155]. - The market for commercial spaceflight is still emerging, and the company’s estimates for the total addressable market may prove to be incorrect[126]. Risks and Liabilities - The company faces significant competition from larger firms with greater resources, which may impact its ability to develop technologies and maintain pricing strategies[154]. - The company’s spaceflight systems may have shorter useful lives than anticipated, leading to higher maintenance costs and potential adverse effects on financial results[151]. - The company is involved in various legal proceedings, including class action lawsuits, which could divert management's attention and incur significant expenses[209]. - The company’s insurance coverage may be inadequate to cover liabilities related to operational risks, potentially harming its financial condition[208]. - Liability for environmental contamination can be strict and joint, potentially leading to significant financial implications for the company[217].

Tokenization and Digital Securities - In 2023, the company launched the DeltaCat Re Token, the first "on-chain" reinsurance security developed by a public company subsidiary, with a total offering of up to $5.0 million at $10.00 per token[18][26]. - The Private Placement for DeltaCat Re Tokens raised $2,447,760, with approximately $1,280,000 from third-party investors and $1,167,000 from the company itself[27]. - The company plans to issue additional tokenized reinsurance securities, including EpsilonCat Re in 2024 and ZetaCat Re and EtaCat Re in 2025, targeting high yield and balanced yield returns[18][29]. - The company intends to leverage its tokenization experience to develop Web3-focused business offerings related to the tokenization of real-world assets[18][43]. - SurancePlus has launched a series of real-world asset-backed digital securities, starting with the DeltaCat Re token issued in 2023 on the Avalanche blockchain[82]. - The 2024/25 offering of EpsilonCat Re tokens was announced on March 18, 2024, with subsequent offerings planned for 2025/26 and 2026/27 on the Solana blockchain[82]. - The company is exploring opportunities in the tokenization of real-world assets (RWAs), with the RWA asset tokenization market projected to reach $16.1 trillion by 2030[81]. - The tokenization business is at an early stage, and its success is uncertain, with potential fluctuations in operational results[94]. Reinsurance Operations and Strategy - The company aims to achieve long-term growth in book value per share by writing fully collateralized reinsurance contracts, primarily focusing on property catastrophes in the Gulf Coast region[19]. - The profitability of the reinsurance operations is influenced by the adequacy of premiums and investment income covering costs, which include acquisition costs and claim payments[20]. - The company employs an opportunistic underwriting strategy, which may lead to significant fluctuations in operational results from period to period[22]. - The company primarily writes property catastrophe reinsurance, expecting that substantially all products will be in the form of treaty reinsurance contracts[53]. - The company anticipates a continued focus on large transactions with a relatively small number of cedants, maintaining a portfolio characterized by a limited number of reinsurance contracts[55][62]. - The company’s contracts are generally written on an excess-of-loss basis, with coverage limits specified per event, and premiums typically earned over a 12-month contract term[49][56]. - The company plans to source the majority of its business through reinsurance brokers, leveraging their established relationships to access a broad range of clients[64][65]. - The company is committed to disciplined underwriting and risk management, focusing on optimizing long-term growth rather than predictable quarterly earnings[37]. - The company anticipates continued opportunities for growth through organic expansion and acquisitions in the reinsurance market[38]. Financial Management and Capital - A Promissory Note was issued for $1,000,000 with a 16% annual interest rate, secured by a Security Agreement, to be used for working capital and general corporate purposes[34]. - The company’s investment strategy is opportunistic, aiming to increase shareholder value through supplemental investment income and potential investments in real estate[67]. - The company may face significant risks related to capital availability and the need for additional funding to support growth[94]. - The reinsurance subsidiaries are subject to minimum capital and surplus requirements, and failure to meet these could lead to regulatory actions[87]. - Oxbridge Re anticipates that SurancePlus may become a significant revenue stream, potentially reducing annual capital deployed into collateralizing reinsurance contracts[83]. - Oxbridge Reinsurance Limited and Oxbridge Re NS are required to maintain a statutory minimum capital requirement of $500 and a prescribed capital requirement of $500[87]. Market Environment and Competition - Florida's property and casualty insurance market has approximately $2.18 trillion in insured residential property exposure, with Hurricanes Helene and Milton causing estimated insured losses exceeding $55 billion in 2024[51]. - The reinsurance industry is highly competitive, with major competitors including Renaissance Re, Berkshire Hathaway, and PartnerRe Ltd, which have strong financial ratings and established client relationships[78][79]. Claims Management and Reserves - Claims management is conducted internally, with a focus on establishing case reserves and auditing clients' claims handling abilities[70][71]. - The company’s loss reserves are based on estimates from ceding companies and independent actuaries, reflecting the inherent uncertainty in predicting future claims[72][74]. Regulatory and Operational Considerations - The company is subject to regulation by the Cayman Islands Monetary Authority, which oversees its Class C Insurer's License[86]. - The company is not currently involved in any litigation or arbitration, but anticipates potential legal challenges typical in the insurance and reinsurance industry[85]. - As of March 26, 2026, the company has four full-time employees and plans to outsource certain functions as necessary[84].

Acquisitions - In November 2024, the company acquired My Home Group for approximately $4.2 million, including $0.3 million in cash and $2.1 million in stock[280]. - In October 2025, the company acquired START Real Estate for approximately $1.2 million, including $0.2 million in cash and $0.3 million in stock[282]. - The company recorded finite-lived intangible assets of approximately $3.2 million and goodwill of approximately $1.4 million from the My Home Group acquisition[280]. - Cash used for acquisitions decreased to $0.2 million in 2025 from $0.8 million in 2024, reflecting a slowdown in acquisition activity[338]. Financial Performance - For the year ended December 31, 2025, My Home Group generated revenue of $126.7 million, which did not materially affect the company's consolidated results[281]. - Total revenue for the year ended December 31, 2025, was approximately $420.5 million, a 25.4% increase from $335.2 million in 2024[320]. - For the year ended December 31, 2025, gross commission income increased by approximately $84.0 million, or 26.7%, compared to 2024, driven by a 14.6% increase in transaction volume to approximately 42,405 real estate transactions[320]. - Adjusted EBITDA for the year ended December 31, 2025, was $(4.0) million, an improvement from $(5.7) million in 2024, indicating a reduction in operational losses[345]. - The company reported a loss before income tax of $20.2 million in 2025, compared to a loss of $22.6 million in 2024, reflecting a narrowing of losses[345]. Operating Expenses - Operating expenses for the year ended December 31, 2025, totaled approximately $436.1 million, an increase of 21.6% from $358.6 million in 2024[323]. - Commission and service costs increased by approximately $79.4 million, or 25.9%, primarily due to higher transaction volume and agent commissions[323]. - General and administrative expenses decreased by approximately $0.5 million, or 1.5%, due to a reduction in stock compensation expense[324]. - Marketing expenses decreased by approximately $0.6 million, or 11.0%, attributed to reduced reliance on external marketing agencies[325]. - Technology and development expenses increased by approximately $0.7 million, or 10.1%, due to ongoing investment in the intelliAgent platform[326]. Cash Flow and Assets - Net cash used in operating activities was approximately $20.5 million for the year ended December 31, 2025, compared to $4.7 million in 2024, primarily driven by changes in mortgage activity[337]. - The company had cash and cash equivalents of approximately $5.8 million as of December 31, 2025, a decrease of $1.4 million from $7.1 million in 2024[334]. - Net cash provided by investing activities was approximately $4.0 million for the year ended December 31, 2025, compared to $3.3 million in 2024, with proceeds from business sales totaling $7.1 million in 2025[338]. - Net cash provided by financing activities increased to $15.0 million in 2025 from $1.2 million in 2024, driven by $9.5 million in gross proceeds from public offerings of common stock[339]. - As of December 31, 2025, current assets were approximately $35.9 million, a 43.9% increase from $25.0 million in 2024[330]. Debt and Financing - Principal debt repayments increased to $4.6 million in 2025 from $0.6 million in 2024, while no new debt was issued in 2025[339]. - Borrowings under warehouse lines of credit increased to $246.9 million in 2025 from $233.3 million in 2024, indicating a rise in transaction volume[339]. Market Performance - The average sales price for existing homes in December 2025 was $405,400, up 0.4% from December 2024[295]. - Existing home sales in 2025 totaled approximately 4.06 million units, representing little growth from 2024[290]. - The company's real estate agent licenses decreased by 1.2% to approximately 14,135 as of December 31, 2025[301]. Future Outlook - The company aims to achieve positive total company Adjusted EBITDA for the full year 2026[297]. - The company believes that the estimated fair values of reporting units continue to exceed their carrying values, indicating no impairment of goodwill[351]. Business Performance - The company experienced a gain on the sale of business of $922,000 in 2025, compared to a loss of $2.96 million in 2024, suggesting improved performance in business divestitures[345]. - Purchases of intangible assets decreased to $2.8 million in 2025 from $3.2 million in 2024, indicating a reduction in investment in intangible assets[338].

Revenue and Loss - Revenue for the year ended December 31, 2025, was $1.82 million, a decrease of 33% from $2.72 million in 2024[362]. - The company reported a net loss before provision for income taxes of $52.23 million for 2025, compared to a loss of $3.62 million in 2024[355]. - The loss on change in fair value of digital assets was $166.09 million, reflecting a decline in Bitcoin price from $114,078 to $87,519 per Bitcoin[360]. - The loss on investments for 2025 was $9.92 million, primarily due to a decline in the fair value of Metaplanet common stock[361]. - The company experienced a loss on the acquisition of Nakamoto Holdings amounting to $59.8 million due to the difference between the fair value of shares issued and net liabilities acquired[371]. Operating Expenses - Total operating expenses for 2025 were $198.96 million, significantly up from $6.07 million in 2024, primarily due to costs associated with the Nakamoto Merger[355]. - General and administrative expenses increased to $11.76 million in 2025 from $1.91 million in 2024, largely due to transaction-related costs from the Nakamoto Merger[364]. Cash Flow and Liquidity - The company reported a net cash used in operating activities of $23.5 million for the year ended December 31, 2025, compared to $3.1 million in 2024, primarily due to an increase in net loss[377]. - The net cash used in investing activities was $680.0 million for the year ended December 31, 2025, significantly higher than $0.4 million in 2024, due to the net purchase of 5,342 Bitcoin[378]. - The net cash provided by financing activities was $723.8 million for the year ended December 31, 2025, compared to $5.2 million in 2024, driven by PIPE financings and proceeds from debt[379]. - The company’s liquidity is primarily supported by Bitcoin holdings, cash, and equity securities sales, with cash requirements focused on debt servicing and overhead expenses[368]. - As of December 31, 2025, the company held approximately 1,625 unencumbered Bitcoin worth approximately $142.2 million, cash and cash equivalents of $22.6 million, and an investment in publicly traded stock of $20.7 million[370]. Acquisitions and Investments - The acquisition of BTC Inc and UTXO on February 20, 2026, involved issuing 364,795,104 shares valued at $81.6 million[352]. - The fair value of the call option to acquire BTC Inc increased by $226.4 million as of December 31, 2025, allowing the company to purchase BTC Inc at $1.12 per share[371]. - The company plans to use proceeds from the sale of approximately 284 Bitcoin for $20 million to invest further in its businesses and replenish working capital[370]. Debt and Financing - The company entered into a Master Loan Agreement with Kraken for a loan of 210.0 million USDT at an 8.0% fixed rate, maturing on December 4, 2026, with 3,717 of its 5,342 Bitcoin held as collateral[369]. - The company approved a 2025 Repurchase Program to buy back up to $10 million worth of its Common Stock, with approximately $0.7 million repurchased by December 31, 2025[375]. Business Strategy - The company intends to exit its legacy healthcare business as of March 2026[365]. - As of December 31, 2025, the company held approximately 5,342 Bitcoin with a carrying value of $467.5 million, highlighting the significant market risk associated with Bitcoin price volatility[392][393].

Customer Base and Engagement - Lulus has 2.3 million Active Customers as of December 28, 2025, indicating a strong customer base[40] - The company has over 8.9 million followers across social media platforms, enhancing customer engagement and brand loyalty[33] - Lulus aims to enhance its Love Rewards® loyalty program to drive repeat purchase behavior and increase customer engagement[42] - A significant portion of the company's net revenue comes from repeat purchases by existing customers, highlighting the importance of customer retention for financial stability[94] - The company has cultivated a significant presence on TikTok, particularly among Gen Z customers, making potential restrictions on this platform a considerable risk to customer engagement and brand promotion[103] Business Strategy and Operations - The wholesale business grew 144% year-over-year from fiscal 2024 to 2025, showcasing significant expansion in this channel[45] - Lulus utilizes a "test, learn, and reorder" strategy to bring new products to market almost every week, optimizing profitability and minimizing risk[29] - The company has a vertically integrated business model, retaining control over brand, product, marketing, distribution, and customer service[56] - The company plans to expand its channel reach through wholesale partnerships with major retailers like Nordstrom and Amazon[45] - The company is investing in AI and generative AI technologies to enhance the customer shopping experience, indicating a focus on technological advancement[89] Financial Performance - In 2025, the company recognized 23%, 29%, 26%, and 22% of its annual net revenue during the first, second, third, and fourth quarters, respectively[57] - The company experienced net losses of $14 million, $55 million, and $19 million in the fiscal years ended December 28, 2025, December 29, 2024, and December 31, 2023, respectively[137] - Net revenue increased from $133 million in 2016 to $282 million in 2025, with fluctuations attributed to the COVID-19 pandemic and subsequent macroeconomic pressures[139] Employee and Workplace Practices - The company has 523 full-time and 6 part-time employees as of December 28, 2025, with no labor-related work stoppages reported[73] - The company offers competitive compensation and benefits to attract and retain talent, including health insurance and a 401(k) plan[79] - The company emphasizes continuous improvement and employee development as part of its core values, fostering a culture of learning[78] - The company has a proactive approach to employee health and safety, with dedicated safety teams in distribution centers[80] Supply Chain and Sourcing - The company collaborates with around 250 suppliers, ensuring priority access and exclusivity to designs[47] - The company sources nearly all merchandise from third-party suppliers, exposing it to price fluctuations and demand disruptions, which could negatively impact operations[194] - The company is working to establish more direct sourcing relationships with factories, which introduces risks related to shipping, importation, and payment terms[194] - The company plans to increase direct sourcing relationships with overseas manufacturers to mitigate supply chain challenges, but acknowledges limited experience may expose it to unforeseen risks[214] Regulatory and Compliance Issues - The company is subject to evolving privacy and data security regulations, including the California Consumer Privacy Act and the General Data Protection Regulation[62][65] - The company has implemented a Vendor and Supplier Code of Conduct to ensure responsible sourcing and production practices[70] - The company is subject to California's SB 62 and AB 701, which impose obligations related to garment worker protections and warehouse worker quotas[216] - Regulatory changes related to e-commerce and internet laws could adversely affect the company's business operations and financial performance[224] Market and Competitive Landscape - The company operates in a highly competitive retail apparel industry, facing significant competition from both national and international retailers, as well as e-commerce platforms, which could adversely impact growth and market share[147] - The competitive landscape is subject to rapid changes, with new competitors emerging and existing ones altering their offerings, which could affect the company's ability to compete successfully[148] - The apparel industry is characterized by intense pricing pressure, exacerbated by low barriers to entry and supply chain constraints[144][146] Risks and Challenges - The company faces risks related to customer complaints and negative publicity, which could harm brand reputation and financial results[83] - The company is exposed to risks associated with changes in international trade regulations, which could disrupt sourcing strategies and forecasting margins[122] - The company relies heavily on digital platforms for customer acquisition, and changes in algorithms or policies by these platforms could adversely affect traffic and customer engagement[98] - The company faces significant risks related to system security, including potential breaches that could adversely affect its business and financial condition[168] Technology and Data Management - The implementation of a data warehouse solution has enabled the company to integrate data from various sources, enhancing business intelligence and predictive analysis capabilities[175] - The company is actively updating its technology systems, which may disrupt operations and incur substantial additional expenses[183] - The reliance on third-party service providers for data processing and security increases vulnerability to security incidents, which could lead to legal liabilities and reputational harm[172] Economic Factors - Economic downturns and macroeconomic conditions have led to reductions in net revenue during 2023, 2024, and 2025, as consumers generally lowered their spending levels on discretionary items[153] - The company relies on consumer discretionary spending, which may decline during recessionary periods or times of economic uncertainty, adversely affecting sales[154] - Increased tariffs on goods imported from China have reached as high as 152.5%, significantly impacting the company's cost of sales and pricing strategies[121]

Acquisition and Development - The company completed the acquisition of Faeth Therapeutics on February 17, 2026, which included a lead asset, PIKTOR, and received $200 million in gross proceeds from a private placement financing[15] - The acquisition of Faeth Therapeutics is expected to advance PIKTOR through key clinical milestones, supported by a broad syndicate of investors[15] - The company has not yet initiated an independent clinical trial of PIKTOR in ovarian or lung cancer, with future development dependent on regulatory discussions and ongoing trial results[102] Clinical Trials and Efficacy - PIKTOR is currently in a Phase 2 trial for second-line advanced endometrial cancer, with topline data expected by year-end 2026, and a Phase 1b trial for HR+/HER2- advanced breast cancer is planned to start in the first half of 2026[17] - The objective response rate (ORR) in the Phase 1b trial was 47%, with a clinical benefit rate (CBR) of 73% among evaluable patients[62] - Median progression-free survival (PFS) was reported at 11 months, while overall survival (OS) reached 17 months in the same trial[62] - PIKTOR demonstrated an 80% objective response rate (ORR) in five heavily pretreated endometrial cancer patients, with a median PFS of 11 months[88] - The ongoing Phase 2 trial of PIKTOR in endometrial cancer anticipates topline data by year-end 2026, with the last patient expected to be dosed in 2027[96] - The DICE trial showed a 34% decrease in risk of disease progression (HR=0.66) with the addition of sapanisertib to paclitaxel, with mean PFS of 5.8 months versus 4.0 months for paclitaxel alone[98] - PIKTOR's planned Phase 1b trial will evaluate escalating doses in advanced HR+/HER2- breast cancer, with interim data expected in 2027 and expansion cohorts in 2028[84] Mechanism and Targeting - The PI3K/AKT/mTOR pathway is dysregulated in up to 50% of all solid tumors, making it a significant target for cancer therapies[16] - PIKTOR is designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway, potentially leading to deeper and more durable tumor suppression compared to single-node inhibitors[39] - PIKTOR's selective PI3Kα inhibition may reduce the risk of off-target toxicities associated with pan-PI3K inhibitors, enhancing its clinical profile[45] - PIKTOR's development targets significant unmet needs in oncogenesis and tumor progression related to dysregulated PI3K/AKT/mTOR pathway activity[65] Safety and Tolerability - PIKTOR demonstrated a tolerability profile with only one dose-limiting toxicity observed, and most adverse events were mild or moderate[63] - In the ongoing Phase 2 trial, stomatitis occurred in 13.6% of patients (0% grade 3/4) and hyperglycemia in 13.6% (4.5% grade 3/4)[64] - PIKTOR's combination therapy has been well tolerated in approximately 1,050 patients across multiple studies, with 152 patients receiving the drug[58] - The company believes PIKTOR may provide more comprehensive and tolerable PI3K/AKT/mTOR pathway inhibition than current therapies[59] Market Potential and Competition - The total addressable market for second-line HR+/HER2- breast cancer and advanced endometrial cancer in the U.S. is estimated to be approximately $6 billion, with HR+/HER2- breast cancer accounting for about $5 billion[148] - The company faces competition from various biotechnology and pharmaceutical firms, which may have greater financial resources and established market presence[108] - The competitive landscape includes several product candidates in clinical development that pose a direct threat to PIKTOR, particularly for advanced HR+/HER2- breast cancer[111] Regulatory and Compliance - The FDA requires the submission of an Investigational New Drug application (IND) before human clinical trials can begin, which becomes effective 30 days after receipt unless placed on clinical hold[151] - Clinical trials must be conducted in three phases: Phase 1 focuses on safety and dosage, Phase 2 evaluates efficacy and safety in a limited patient population, and Phase 3 provides substantial evidence of efficacy in a larger population[160] - The FDA aims to review a standard NDA for a new molecular entity within ten months from the filing date, with a typical review taking twelve months from submission[163] - The FDA may issue an approval letter for commercial marketing or a Complete Response Letter (CRL) detailing deficiencies in the NDA, which must be addressed before resubmission[165] - The FDA may require a risk evaluation and mitigation strategy (REMS) for approved drugs to ensure safe use, which could limit marketing and distribution[166] Financial Obligations and Royalties - The company is obligated to pay tiered single-digit royalties on annual net sales of Serabelisib Products, with obligations commencing on the first commercial sale[122] - The company is obligated to pay up to $119 million in development, regulatory, and commercial launch milestone payments, and up to $250 million in sales milestone payments for PIKTOR and related products[132] - The royalty payments for PIKTOR Products will commence on the first commercial sale and continue for up to 10 years or until the expiration of relevant patents, whichever is later[133] Intellectual Property - The patent portfolio for PIKTOR includes 13 issued U.S. patents and four pending U.S. applications, with expiration dates ranging from 2027 to 2046[114] - Intellectual property is crucial for the company, with efforts to protect and enhance proprietary technology through patents and trade secrets[112] Future Developments - The company is engaged in ongoing Chemistry, Manufacturing, and Controls (CMC) development to support potential future registrational trials and New Drug Application submissions[146] - The company has not yet established a commercial organization or distribution capabilities for its products, despite the substantial market potential[148]

Project Matador Development - Fermi Inc. is developing Project Matador, a hyperscale power and AI infrastructure campus with a potential capacity of up to 17 GW, aimed at supporting AI-centric customers[25]. - Project Matador is designed to support approximately 15 million square feet of AI-ready hyperscale compute infrastructure over a multi-decade buildout timeline[26]. - Project Matador is currently in Phase 1, focusing on initial commercial energization and tenant commissioning, with an expected initial power delivery of up to 200 MW[58]. - The project aims to achieve approximately 2.5 GW of gas-fired power capacity by the end of 2028, contingent on tenant lease agreements and financing[60]. - Upon full buildout, Project Matador is designed to include approximately 6.0 GW of nuclear capacity and up to 6 GW of natural gas-fired generation, totaling approximately 11 GW of generation capacity[67]. - The project has mobilized around 500 engineers and construction personnel to execute Phase 0 scope within the first nine months of construction[57]. - The campus design includes integrated water treatment systems and infrastructure for AI training, aimed at supporting mission-critical, AI-driven digital workloads[68]. - The company has secured a 99-year ground lease covering approximately 5,236 acres, with plans to expand the campus footprint to approximately 7,570 acres[50]. - The company has expanded its land position by acquiring approximately 2,000 additional acres, which supports future campus phases and utility corridor development, potentially increasing total generation capacity to approximately 17 GW[98][99]. Financial Projections and Revenue Generation - The company anticipates generating revenue primarily from long-term tenant lease arrangements, with payments structured around reserved power capacity and service levels[40]. - The company expects to generate limited non-operating income until definitive lease agreements are executed and powered shells are delivered[30]. - The company plans to elect to qualify as a REIT for U.S. federal income tax purposes starting with the taxable year ending December 31, 2025[29]. - The company plans to finance its campus through a mix of equity capital, tenant-funded amounts, and project-level non-recourse or limited-recourse debt, while also considering monetization of eligible tax credits[136]. - The company has not yet constructed its facilities or entered into any binding contracts with tenants, which poses significant execution risks[189]. - The company has generated no revenue to date and does not expect to do so until the first half of 2027, contingent on executing definitive lease agreements[189]. - The company expects to incur significant financial losses until Project Matador becomes commercially viable, necessitating substantial future funding to support operations and growth plans[193]. Infrastructure and Capacity - The total AI power demand is projected to grow from 55 GW in 2023 to 219 GW by 2030, requiring an estimated $5.2 trillion in related infrastructure investment[31]. - U.S. data center demand is expected to reach between 1,000 terawatt-hours and over 1,534 terawatt-hours per year by 2030, driven by a compound annual growth rate of 33% in AI capacity demand[32]. - The rise in power density for AI workloads is leading to increased demand for private power solutions, with new deployments requiring between 100 MW to 1,000 MW[35]. - The company has secured up to 200 MW of grid-supplied capacity, with the first 86 MW expected to be energized in the second half of 2026 and the remaining 114 MW potentially extending into 2027[74][75]. - The total simple cycle capacity under the company's control is expected to expand to approximately 1.5 GW, with staged energization and commercial operation beginning in the first half of 2027[76][78]. - The gas-fired generation portfolio could produce nearly 2.0 GW of power by the end of 2027, including 1.5 GW in simple cycle mode and roughly 500 MW of combined cycle back-end generation capability[84][96]. Regulatory and Compliance Challenges - The company is subject to extensive federal, state, and local regulations, which may materially affect project timing, costs, and operations[153]. - The company is subject to complex regulatory requirements that may delay or restrict project development[188]. - The company has received approval for an air permit associated with up to approximately 6 GW of natural gas-fired generation at Project Matador, with an additional application for 5 GW pending[155]. - The company faces challenges in executing its multi-gigawatt powered campus strategy, including securing tenant commitments and financing long-lead infrastructure[137]. Risks and Market Competition - The compute infrastructure market is rapidly evolving, with competition from various market participants for tenant commitments and development sites[146]. - The company faces competition from established players with greater access to capital and fewer regulatory hurdles, which could hinder its market position[208]. - The ongoing geopolitical issues and supply chain disruptions have affected the availability of necessary resources for Project Matador[202]. - The AI and hyperscaler market's adoption of the company's private infrastructure platform may not occur at the anticipated speed or scale, impacting business prospects and financial condition[210]. - Significant liquidated damages may arise if the company fails to meet milestones in tenant leases, adversely affecting financial condition and cash flows[217]. - Failure to meet specific project milestones could lead to substantial liquidated damages and potential insolvency, as lease terminations would result in loss of revenue[218]. - The company relies on a complex ecosystem of third-party vendors and contractors, and any issues with these parties could adversely affect project delivery and tenant attraction[221]. Technological and Operational Considerations - The rapid pace of technological advancements in AI and compute infrastructure may outpace the company's development cycle, leading to potential obsolescence of its offerings[212]. - The company relies heavily on third-party suppliers for materials, which poses risks of increased costs, delays, and potential revenue loss due to manufacturing capacity constraints[201]. - The company has identified a material weakness in its internal control over financial reporting, which could impair its ability to produce timely and accurate financial statements[187]. - Cybersecurity threats and potential attacks could compromise the integrity of the company's hybrid grid systems, impacting financial condition and operations[223]. Board Composition and Governance - The board currently consists of 4 men and 0 women, failing to meet the standard of at least 40% female representation[175]. - The company has one ethnic minority member on the board, meeting the requirement for at least one member from an ethnic minority[175].

Royalty Income and Distributions - The Trust owns an overriding royalty interest equal to 11.44% of 90% of the Net Proceeds from specified oil and gas properties[14]. - The Trust's Royalty income must exceed $250,000 per year for two consecutive years to avoid termination[21]. - The Monthly Distribution Amount is determined based on cash received from the Royalty, minus obligations paid during the month[28]. - The Trust distributes cash to unitholders in January, April, July, and October, rather than monthly, to reduce administrative expenses[28]. - The Trust's Royalty is derived from oil, gas, and other minerals produced from properties since November 1, 1979[23]. - The Trust's estimated future net revenue from Royalty income as of December 31, 2025, totals $24,627,000, with contributions of $1,118,000 from Simcoe, $23,333,000 from Hilcorp, and $176,000 from Scout[58]. - The Trust's distributions are generally subject to backup withholding at a current rate of 24% unless the unitholder provides a correct taxpayer identification number[39]. - Non-U.S. unitholders are subject to a 30% tax on gross income from Royalty, which may be reduced by applicable treaties[43]. - The Trust's Royalty income is highly dependent on natural gas prices, which can fluctuate widely and affect distributions to unitholders[182]. - Royalty income for the year ended December 31, 2025, was $601,840, a decrease from $649,164 in 2024, primarily due to lower pricing for natural gas liquids and oil[192]. Financial Management and Expenses - As of December 31, 2025, there were $0 of unreimbursed expenses, indicating efficient management of administrative costs[29]. - The Working Interest Owners reimburse the Trust for general and administrative expenses at rates of 59.34%, 27.45%, and 1.77% respectively[21]. - General and administrative expenses were reduced to $171,832 in 2025 from $196,399 in 2024, indicating improved cost management[194]. - The Trust incurred no unreimbursed expenses for both 2025 and 2024, maintaining a stable expense profile[196]. - The Trust does not have any material commitments for capital expenditures as it is a passive entity[188]. Production and Reserves - The Trust's total proved gas reserves as of December 31, 2025, amount to 5,885 million cubic feet (MMcf), with 1,378 MMcf from Simcoe, 4,469 MMcf from Hilcorp, and 38 MMcf from Scout[57]. - The Trust's total proved developed oil and condensate reserves are 8,000 barrels, with 8,000 barrels attributed to Hilcorp[57]. - The quantities of reserves attributable to the Royalty Properties increased in 2025 but may decrease due to falling prices of oil and natural gas[115]. - The average production costs for natural gas in 2025 were $3.68 per Mcf, compared to $2.64 per Mcf in 2024, indicating a 39% increase[66]. - Net production volumes attributable to the Royalty for 2025 were 172,715 Mcf of natural gas, down from 195,665 Mcf in 2024, representing a decrease of 12%[66]. - The average sales price for natural gas was $3.80 per Mcf, an increase from $3.02 per Mcf in 2024, reflecting a 26% increase[66]. Market Conditions and Commodity Prices - The Trust's cash distributions are highly dependent on sales prices and quantities of gas sold, which can vary seasonally[70]. - The volatility of energy prices reduces the predictability of future cash distributions to unitholders[100]. - The Trust's financial condition could be materially adversely affected by declines in natural gas prices, which may lead to reduced net royalties[104]. - The average Henry Hub Natural Gas Spot Prices increased from $2.19 per MMBtu in 2024 to $3.52 per MMBtu in 2025, a rise of 60%[70]. - Crude oil prices were $57.42 per barrel as of December 31, 2025, and increased to $90.32 per barrel by March 25, 2026, driven by geopolitical tensions[102]. Regulatory and Environmental Factors - The Trust's operations are subject to various environmental regulations, which could impose additional costs and liabilities[91]. - The Working Interest Owners maintain insurance for cleanup obligations but are not fully insured against all environmental risks[89]. - The production and sale of natural gas are influenced by various regulatory factors, including potential future price controls by Congress[74][77]. - Climate change legislation may impose additional costs on the Trust, potentially affecting Trust distributions due to increased operating expenses[139]. Risks and Uncertainties - The Trust's reliance on third-party reserve engineers for reserve estimates introduces uncertainties in the accuracy of reserve data[64]. - Cyber-attacks and IT system failures pose significant risks to the operations and financial condition of the Working Interest Owners, potentially affecting Trust distributions[129]. - The Trust has limited ability to enforce its rights against Working Interest Owners, which may impact its financial position[146]. - The Trust's financial condition may be impacted by the bankruptcy of any operator of the underlying properties, which could reduce Net Proceeds available to the Trust[151]. - The Trust's competitive position is affected by market conditions, including the limited number of major pipelines in the San Juan Basin[72]. Governance and Structure - The Trust is classified as a grantor trust, incurring no federal income tax liability, with unitholders taxed on their pro rata share of income[32]. - The Trust's unitholders have limited voting rights compared to stockholders of public corporations, affecting governance and decision-making[145]. - The Trust relies on Working Interest Owners for all operating and financial information regarding the Royalty Properties[181]. - The financial statements of the Trust are prepared on a modified cash basis, differing from U.S. GAAP, which may affect the recognition of income and expenses[152].

Financial Performance - Research and development expenses increased to $1.6 million in 2025 from $1.3 million in 2024, reflecting a growth of approximately 23.1%[91] Employee Development - As of March 9, 2026, Precipio employed a total of 61 full-time and 10 part-time employees, with 44 in laboratory and production roles[92] - The company emphasizes employee development, providing training and resources to enhance skills and career growth[94] - Precipio's competitive compensation programs aim to align employee incentives with both short-term and long-term performance[95] Innovation and Technology - The company has filed U.S. and European patent applications for its proprietary HemeScreen technology, reinforcing its commitment to innovation[113] Environmental Responsibility - Precipio published its Environmental, Social, and Governance (ESG) Report in February 2023, highlighting its commitment to responsible business practices[106] - The company actively reduces waste and explores sustainability initiatives to minimize its environmental footprint[108] Compliance and Ethics - Compliance with various privacy laws, including the California Consumer Privacy Act (CCPA), is a priority, impacting business operations and strategies[115] - The company has a robust Code of Business Conduct and Ethics, with training and an anonymous hotline for reporting concerns[99] Leadership - Precipio's executive team includes experienced leaders, such as the CEO and CFO, who bring over 20 years of industry experience[102][103] Regulatory Classification - The company is classified as a smaller reporting company under Rule 12b-2 of the Securities Exchange Act of 1934, thus not required to provide detailed market risk disclosures[397]

Clinical Trials and Development - The company is developing REQORSA® Gene Therapy for Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC), with a recommended Phase 2 dose of 0.12 mg/kg administered every 21 days[515]. - In the Phase 1 portion of the Acclaim-1 trial, three out of twelve patients experienced prolonged progression-free survival, with one patient maintaining a partial remission for approximately 42 months[515]. - The Acclaim-1 trial has received FDA Fast Track Designation for the combination treatment of REQORSA and Tagrisso in NSCLC patients[516]. - The Phase 2a expansion of the Acclaim-3 trial is expected to enroll approximately 50 patients, with an interim analysis planned after the first 25 patients reach 18 weeks of follow-up[519]. - The Acclaim-2 trial, which involved a combination of REQORSA and Keytruda, has been closed due to slow enrollment and competition for eligible patients[518]. - The Phase 2 expansion portion of the Acclaim-3 trial aims to determine the 18-week progression-free survival rate in patients with extensive stage small cell lung cancer[519]. - The company is collaborating with MD Anderson to identify biomarkers that may predict patient response to REQORSA in lung cancer treatments[514]. Financial Performance - Research and development (R&D) expense decreased by $1,106,726, or 11%, to $9,428,720 for the year ended December 31, 2025, primarily due to the closure of the Acclaim-2 clinical trial and a reduction in R&D staff from 9 to 7 employees[543]. - General and administrative (G&A) expense decreased by $4,545,129, or 43%, to $6,086,899 for the year ended December 31, 2025, mainly due to one-time charges and a significant reduction in share-based compensation[544]. - Net loss for the fiscal year ended December 31, 2025, was $16,228,953, a decrease of $4,882,210, or 23%, compared to a net loss of $21,111,163 for the fiscal year ended December 31, 2024[547]. - As of December 31, 2025, the accumulated deficit was $171,028,396, with no revenue generated from product sales since inception[549]. - Interest income decreased to $26,900 for the year ended December 31, 2025, from $63,574 in 2024, primarily due to lower cash balances in interest-bearing accounts[545]. - Depreciation expense was $0 for the year ended December 31, 2025, compared to $6,693 in 2024, reflecting changes in accounting policies[546]. Capital and Funding - For the year ended December 31, 2025, the company sold 1,602,490 shares of common stock for net proceeds of approximately $10.8 million under the 2023 ATM Facility[551]. - The company entered into a Purchase Agreement with Lincoln Park for an equity line of credit of up to $12.5 million over 24 months, subject to certain conditions[552]. - As of December 31, 2025, the company had $7,830,855 in cash and received net proceeds of approximately $13.3 million through its 2023 ATM Facility after year-end[554]. - The company anticipates needing to raise additional capital to fund ongoing clinical trials, including Acclaim-1 and Acclaim-3, which are currently enrolling[555]. - The company has registered $75 million of shares for sale under the ATM, with approximately $58.6 million remaining unsold as of the report date[553]. - The company expects to fund its operations into the second quarter of 2027 but will require additional fundraising activities by that time[559]. Strategic Considerations - The company plans to retain its oncology clinical development programs while potentially transferring its diabetes clinical development program to a new subsidiary, Convergen Biotech, Inc.[524]. - The company is considering various strategic alternatives to enhance stockholder value, including optimizing clinical and research programs[537]. - The company expects R&D expenses to increase in the future as it advances product candidates through clinical trials and expands research programs[537]. - The company faces uncertainty regarding its ability to maintain liquidity and continue as a going concern over the next 12 months due to recurring losses and the need for additional financing[555]. - The company experienced delays in clinical trial enrollment due to competition for patients and operational transitions, which may impact capital resource utilization[556]. - The company does not expect to generate revenue from product sales until successful development and regulatory approval of its product candidates, which is subject to significant uncertainty[555].